# ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

> **NCT02009579** · PHASE2 · COMPLETED · sponsor: **Belgian Gynaecological Oncology Group** · enrollment: 120 (actual)

## Conditions studied

- Uterine Cervical Neoplasms

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02009579
- **Lead sponsor:** Belgian Gynaecological Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2021-01
- **Final completion:** 2023-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02009579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02009579, "ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02009579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*